---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-024911"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:09:07.957498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025

## Summary
- Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.
- Topline Phase 1 biomarker and safety data for OV329 (GABA-AT inhibitor) expected in Q3 2025.
- OV350 KCC2 direct activator dosed in Phase 1 in Q1 2025; safety/tolerability results expected Q4 2025.
- Q1 net loss $10.2M ($0.14/sh) vs $11.7M ($0.17/sh) a year ago; total op expenses down 28% to $12.7M.
- Oral KCC2 candidate OV4071 on track to initiate proof-of-concept study in H1 2026.

## SEC filing metadata
- accession: 0001628280-25-024911
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/0001628280-25-024911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-024911
- JSON: https://secwatch.observer/filing/0001628280-25-024911.json
- Plain text: https://secwatch.observer/filing/0001628280-25-024911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.